Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Garry, US
Cynthia Garry, Dillsburg, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090165731 | Scratching and self-grooming tool - A self-grooming tool for mammals consists of a quadrilateral pad which has a front face having a plurality of teeth extending therefrom, a rear face and opposed peripheral end and side walls, the opposed peripheral walls having complementary configurations. A recess in the rear face defines two planar areas, the pad being foldable about the recess between a flat position and a folded position. One each of the peripheral end and side walls have laterally projecting flanges, the underside of each flange being co-planar with the rear face of the pad and the flanges having a thickness which is less than about one-half the thickness of the pad. The other of each of the peripheral end and side walls have lengthwise extending undercuts formed therein, having the same shape and dimensions as the flanges, and communicating with the rear face of the pad. | 07-02-2009 |
John R. Garry, Itasca, IL US
| Patent application number | Description | Published |
|---|---|---|
| 20110300744 | E-Z RETRACTABLE CORD SYSTEM - A retractable extension power cord comprising: a plastic, circular (cylindrical) housing having at least a first and a second outlet; a spooler for holding power cord; a retractable power cord having a male end retractable out of a first outlet and a female end accessible out of a second outlet, a mounting bracket mountable onto a vertical or horizontal surface; and a ground fault circuit interrupter. The male end is directly connectable to a receptacle while the female end is directly or indirectly connectable to a power source. The retractable power cord communicates power between the male end and the female end The retractable extension power cord provide a means for neatly storing and organizing extension cords while also providing retracting and reverse-retracting capabilities during in-use and non-use periods. Further, the retractable extension cord is reversible and lockable. | 12-08-2011 |
Ken Garry, El Cajon, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20120004619 | NEEDLE PROTECTIVE DEVICE - A needle protective device is provided for reducing inadvertent needle sticks. The needle protective device includes a tubular member that is attached to a base cap. A spring and a shield are positioned in the base cap to selectively cover an access hole of the chamber so that after use of the needle, a needle tip and blood-borne pathogens on the needle are encased within the base cap. The device is selectively pre-activated and is configured such that when activated, the needle tip is contained in the base cap and the device becomes un-usable. | 01-05-2012 |
Mary Garry, Dallas, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20090068148 | PEPTIDES OF CAV2.2 THAT INHIBIT PAIN - The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the interaction of CaV2.2 with Mint1-PDZ1. The invention is related to use of this peptide to treat pain and to use of this peptide in binding reaction with int-PDZ to screen for small molecules that can inhibit pain. | 03-12-2009 |
Michael P. Garry, Rockford, IL US
| Patent application number | Description | Published |
|---|---|---|
| 20120045348 | Integral Plus Proportional Dual Pump Switching System - A dual-pump fluid distribution system that includes a first pump having an inlet and an outlet, and configured to supply a first flow of fluid, and a second pump having an inlet and an outlet, and configured to supply a second flow of fluid. In an embodiment, a bypass flow valve with a four-way hydraulic bridge is configured to initiate the switch between single-pump mode and dual-pump mode based on fluid flow demand. The bypass flow valve is configured such that the position of the bypass flow valve member relative to the four-way hydraulic bridge operates a pump selector valve. In an embodiment, the pump selector valve has a valve member, a biasing element, and a pressure switching port, and is configured such that the position of the valve member determines whether the second flow of fluid is combined with the first flow of fluid. | 02-23-2012 |
Renner Garry, Easley, SC US
| Patent application number | Description | Published |
|---|---|---|
| 20110096521 | ELECTRONIC PASSIVE DEVICE - A capacitive interposer, electronic package having the capacitive interposer and electronic device with the electronic package is described. The interposer has a first planar face and a second planar face. An array of upper connections is on the first planar face and opposing lower connections are on the second planar face with conduction paths between each upper connection of the upper connections and a lower connection of the lower connections. At least one power feed-through capacitor is provided. The capacitor has a plurality of parallel plates with a dielectric there between. At least one first external termination is in electrical contact with a first set of alternate parallel plates and at least one second external termination is in electrical contact with a second set of alternate parallel plates. The capacitor is mounted on the first planar face with the first external termination in direct electrical contact with a first upper connection and the second external termination is in direct electrical contact with a second upper connection. At least one upper connection, first external termination and second external termination are arranged for direct electrical contact with element contact pads of a common element. | 04-28-2011 |
Robert Garry, New Orleans, LA US
| Patent application number | Description | Published |
|---|---|---|
| 20110112031 | OPTIMIZED DENGUE VIRUS ENTRY INHIBITORY PEPTIDE (DN81) - The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds. | 05-12-2011 |
Robert F. Garry, New Orleans, LA US
| Patent application number | Description | Published |
|---|---|---|
| 20080241156 | Inhibitors of hepatitis C virus - The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important for interactions with cellular or viral proteins that are necessary for early steps in HCV infection. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by hepatitis C virus and related viruses. | 10-02-2008 |
| 20090209464 | Flavivirus fusion inhibitors - The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses. | 08-20-2009 |
| 20090264362 | Influenza virus inhibiting peptides - The present invention provides a pharmaceutical composition for the treatment or prevention of an influenza infection. The composition comprises an isolated polypeptide including a sequence of at least 8 contiguous amino acid residues of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or a peptide analog of the sequence. The FIR is a segment of the full length hemagglutinin 2 protein which is bounded by an amino-terminal region within the amino-terminal alpha-helix thereof and a carboxy terminus within the carboxy-terminal alpha-helix thereof, with a cysteine loop therebetween. The amino-terminal region of the FIR comprises a portion of the final 10 to 20 amino acid residues of the amino-terminal alpha-helix of the hemagglutinin 2 protein, and includes 3 or 4 hydrophobic amino acid residues, a positively-charged amino acid residue, a negatively-charged amino acid residue, and an aromatic amino acid residue. The carboxy terminus of the FIR is the carboxy terminus of the first peptide sequence of the hemagglutinin 2 protein beyond the amino terminal helix, which exhibits a positive Wimley-White interfacial hydrophobicity. | 10-22-2009 |
| 20100152109 | Influenza inhibiting compositions and methods - The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR. | 06-17-2010 |
| 20100261640 | SOLUBLE AND MEMBRANE ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS - The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses. | 10-14-2010 |
| 20110130328 | FLAVIVIRUS FUSION INHIBITORS - The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful for treating and preventing a Flavivirus invention. Pharmaceutical compositions comprising the peptides, and methods of treating or preventing Flavivirus infections, are also provided. | 06-02-2011 |